{"id":82343,"date":"2018-08-24T00:00:00","date_gmt":"2022-11-09T14:12:11","guid":{"rendered":"https:\/\/mdbc1.wpengine.com\/?post_type=eb_course&p=82343"},"modified":"2023-05-02T09:24:21","modified_gmt":"2023-05-02T13:24:21","slug":"type-2-diabetes-t2d-evaluating-emerging-insulin-therapies-qicpd-category-2","status":"publish","type":"eb_course","link":"http:\/\/www.mdbriefcase.com\/fr\/courses\/type-2-diabetes-t2d-evaluating-emerging-insulin-therapies-qicpd-category-2\/","title":{"rendered":"Type 2 Diabetes (T2D): Evaluating Emerging Insulin Therapies – QI&CPD – Category 2"},"content":{"rendered":"

The availability of new insulin therapies has led to new opportunities in the management of type 2 diabetes (T2D), with insulin analogues and combinations demonstrating evidence-based improvements in hypoglycaemia, weight change, and cardiovascular risk factors\/outcomes. This module examines two newer insulin therapies: the first is premixed basal insulin plus rapid acting insulin (RAI combination), and the second is single-injection fixed-ratio combinations of basal insulin plus glucagon-like peptide-1 (GLP-1) receptor agonist (Note that these are not yet available in Australia). As hypoglycaemia is a major obstacle for patients with T2D to achieve glycaemic targets, this module will focus on the effects of newer insulin therapies on hypoglycaemia.<\/p>","protected":false},"featured_media":0,"comment_status":"open","ping_status":"closed","template":"","eb_course_cat":[],"class_list":["post-82343","eb_course","type-eb_course","status-publish","hentry"],"acf":[],"yoast_head":"\nType 2 Diabetes (T2D): Evaluating Emerging Insulin Therapies - QI&CPD - Category 2 - MDBriefCase<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.mdbriefcase.com\/fr\/cours\/type-2-diabetes-t2d-evaluating-emerging-insulin-therapies-qicpd-category-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Type 2 Diabetes (T2D): Evaluating Emerging Insulin Therapies - QI&CPD - Category 2 - MDBriefCase\" \/>\n<meta property=\"og:description\" content=\"The availability of new insulin therapies has led to new opportunities in the management of type 2 diabetes (T2D), with insulin analogues and combinations demonstrating evidence-based improvements in hypoglycaemia, weight change, and cardiovascular risk factors\/outcomes. This module examines two newer insulin therapies: the first is premixed basal insulin plus rapid acting insulin (RAI combination), and […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mdbriefcase.com\/fr\/cours\/type-2-diabetes-t2d-evaluating-emerging-insulin-therapies-qicpd-category-2\/\" \/>\n<meta property=\"og:site_name\" content=\"MDBriefCase\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-02T13:24:21+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.mdbriefcase.com\/courses\/type-2-diabetes-t2d-evaluating-emerging-insulin-therapies-qicpd-category-2\/\",\"url\":\"https:\/\/www.mdbriefcase.com\/courses\/type-2-diabetes-t2d-evaluating-emerging-insulin-therapies-qicpd-category-2\/\",\"name\":\"Type 2 Diabetes (T2D): Evaluating Emerging Insulin Therapies - QI&CPD - Category 2 - MDBriefCase\",\"isPartOf\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/#website\"},\"datePublished\":\"2022-11-09T14:12:11+00:00\",\"dateModified\":\"2023-05-02T13:24:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/courses\/type-2-diabetes-t2d-evaluating-emerging-insulin-therapies-qicpd-category-2\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.mdbriefcase.com\/courses\/type-2-diabetes-t2d-evaluating-emerging-insulin-therapies-qicpd-category-2\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.mdbriefcase.com\/courses\/type-2-diabetes-t2d-evaluating-emerging-insulin-therapies-qicpd-category-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.mdbriefcase.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Course\",\"item\":\"https:\/\/www.mdbriefcase.com\/courses\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Type 2 Diabetes (T2D): Evaluating Emerging Insulin Therapies – QI&CPD – Category 2\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.mdbriefcase.com\/#website\",\"url\":\"https:\/\/www.mdbriefcase.com\/\",\"name\":\"MDBriefCase\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.mdbriefcase.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.mdbriefcase.com\/#organization\",\"name\":\"MDBriefCase\",\"url\":\"https:\/\/www.mdbriefcase.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp\",\"contentUrl\":\"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp\",\"width\":190,\"height\":36,\"caption\":\"MDBriefCase\"},\"image\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Type 2 Diabetes (T2D): Evaluating Emerging Insulin Therapies - QI&CPD - Category 2 - MDBriefCase","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.mdbriefcase.com\/fr\/cours\/type-2-diabetes-t2d-evaluating-emerging-insulin-therapies-qicpd-category-2\/","og_locale":"fr_CA","og_type":"article","og_title":"Type 2 Diabetes (T2D): Evaluating Emerging Insulin Therapies - QI&CPD - Category 2 - MDBriefCase","og_description":"The availability of new insulin therapies has led to new opportunities in the management of type 2 diabetes (T2D), with insulin analogues and combinations demonstrating evidence-based improvements in hypoglycaemia, weight change, and cardiovascular risk factors\/outcomes. This module examines two newer insulin therapies: the first is premixed basal insulin plus rapid acting insulin (RAI combination), and […]","og_url":"https:\/\/www.mdbriefcase.com\/fr\/cours\/type-2-diabetes-t2d-evaluating-emerging-insulin-therapies-qicpd-category-2\/","og_site_name":"MDBriefCase","article_modified_time":"2023-05-02T13:24:21+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.mdbriefcase.com\/courses\/type-2-diabetes-t2d-evaluating-emerging-insulin-therapies-qicpd-category-2\/","url":"https:\/\/www.mdbriefcase.com\/courses\/type-2-diabetes-t2d-evaluating-emerging-insulin-therapies-qicpd-category-2\/","name":"Type 2 Diabetes (T2D): Evaluating Emerging Insulin Therapies - QI&CPD - Category 2 - MDBriefCase","isPartOf":{"@id":"https:\/\/www.mdbriefcase.com\/#website"},"datePublished":"2022-11-09T14:12:11+00:00","dateModified":"2023-05-02T13:24:21+00:00","breadcrumb":{"@id":"https:\/\/www.mdbriefcase.com\/courses\/type-2-diabetes-t2d-evaluating-emerging-insulin-therapies-qicpd-category-2\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mdbriefcase.com\/courses\/type-2-diabetes-t2d-evaluating-emerging-insulin-therapies-qicpd-category-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.mdbriefcase.com\/courses\/type-2-diabetes-t2d-evaluating-emerging-insulin-therapies-qicpd-category-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mdbriefcase.com\/"},{"@type":"ListItem","position":2,"name":"Course","item":"https:\/\/www.mdbriefcase.com\/courses\/"},{"@type":"ListItem","position":3,"name":"Type 2 Diabetes (T2D): Evaluating Emerging Insulin Therapies – QI&CPD – Category 2"}]},{"@type":"WebSite","@id":"https:\/\/www.mdbriefcase.com\/#website","url":"https:\/\/www.mdbriefcase.com\/","name":"MDBriefCase","description":"","publisher":{"@id":"https:\/\/www.mdbriefcase.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mdbriefcase.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.mdbriefcase.com\/#organization","name":"MDBriefCase","url":"https:\/\/www.mdbriefcase.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp","contentUrl":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp","width":190,"height":36,"caption":"MDBriefCase"},"image":{"@id":"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"http:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course\/82343","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course"}],"about":[{"href":"http:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/types\/eb_course"}],"replies":[{"embeddable":true,"href":"http:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/comments?post=82343"}],"version-history":[{"count":0,"href":"http:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course\/82343\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/media?parent=82343"}],"wp:term":[{"taxonomy":"eb_course_cat","embeddable":true,"href":"http:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course_cat?post=82343"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}